- |||||||||| Beianting (bevacizumab biosimilar) / Betta Pharma, Chinese PLA General Hospital, Beijing Mabworks Biotech, TQ-B2302 (bevacizumab biosimilar) / Sino Biopharm
Clinical, P1 data, Journal: A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects. (Pubmed Central) - Sep 14, 2022
P1
This study showed that bevacizumab biosimilar and Bevacizumab had similar pharmacokinetics (PK) parameters and safety in healthy Chinese subjects. This trial was registered in ClinicalTrials.gov (Number: NCT05476341, date registered: 25, Jul 2022) and Drug Clinical Trial Registration and Information Disclosure Platform (Number: CTR20171308, date registered: 16, Nov 2017).
|
